Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0043167 (pertussis)
 19,595 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The removal by phagocytosis of degenerated myelin is central for repair in Wallerian degeneration that follows traumatic injury to axons and in autoimmune demyelinating diseases (e.g., multiple sclerosis). We tested for roles played by the cAMP cascade in the regulation of myelin phagocytosis mediated by complement receptor-3 (CR3/MAC-1) and scavenger receptor-AI/II (SRAI/II) separately and combined in mouse microglia and macrophages. Components of the cAMP cascade tested are cAMP, adenylyl cyclase (AC), Gi, protein kinase A (PKA), exchange protein directly activated by cAMP (Epac), and phosphodiesterases (PDE). PKA inhibitors H-89 and PKI(14-22) amide inhibited phagocytosis at normal operating cAMP levels (i.e., those occurring in the absence of reagents that alter cAMP levels), suggesting activation of phagocytosis through PKA at normal cAMP levels. Phagocytosis was inhibited by reagents that elevate endogenous cAMP levels to above normal: Gi-inhibitor Pertussis toxin (PTX), AC activator Forskolin, and PDE inhibitors IBMX and Rolipram. Phagocytosis was inhibited also by cAMP analogues whose addition mimics abnormal elevations in endogenous cAMP levels: nonselective 8-bromo-cAMP, PKA-specific 6-Benz-cAMP, and Epac-specific 8-CPT-2'-O-Me-cAMP, suggesting that abnormal high cAMP levels inhibit phagocytosis through PKA and Epac. Altogether, observations suggest a dual role for cAMP and PKA in phagocytosis: activation at normal cAMP levels and inhibition at higher. Furthermore, a balance between Gi-controlled cAMP production by AC and cAMP degradation by PDE maintains normal operating cAMP levels that enable efficient phagocytosis.
 ...
PMID:cAMP cascade (PKA, Epac, adenylyl cyclase, Gi, and phosphodiesterases) regulates myelin phagocytosis mediated by complement receptor-3 and scavenger receptor-AI/II in microglia and macrophages. 1634 30

In cultured rat hepatocytes, glucagon increased the phosphoenolpyruvate carboxykinase (PCK1) mRNA by increasing cellular cAMP concentrations. The proinflammatory cytokines rhIL1beta and rhTNF alpha impaired the increase both in cAMP and PCK1 mRNA. Glucose formation from glycogen stimulated by glucagon was also attenuated by the cytokines, very likely due to the attenuation of the cAMP increase. Treatment of hepatocytes with the phosphodiesterase inhibitor IBMX or the inhibitory G-protein (G i) inactivating compound pertussis toxin did not abolish the inhibition of the glucagon-stimulated increase in cAMP by the cytokines indicating that phosphodiesterase and G i were not involved. The activation of adenylate cyclase by forskolin enhanced cAMP and PCK1 mRNA. Again, rhIL1beta and rhTNF alpha attenuated the increase in PCK1 mRNA, however, not that in cAMP. The stimulation of PCK1 mRNA increase with the nonhydrolyzable cAMP analogue CPT-cAMP was inhibited by rhIL1beta and rhTNF alpha indicating interference independent of changes in cAMP levels. It is concluded that rhIL1beta and rhTNF alpha inhibited glucagon-stimulated signal transduction at the site of cAMP formation. In addition, glucagon-stimulated PCK1 mRNA was attenuated independent of cAMP formation very likely on the transcriptional and/or post-transcriptional level.
 ...
PMID:Inhibition of glucagon-signaling and downstream actions by interleukin 1beta and tumor necrosis factor alpha in cultured primary rat hepatocytes. 1833 79


<< Previous 1 2 3